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Abstract
Background: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate
is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are
remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is
miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of
this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer.
Methods: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain
reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues.
The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier
analysis and Cox proportional hazards model.
Results: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in
normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with
human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and
P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International
Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular,
high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced
FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01).
Conclusions: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a
potential therapeutic target.
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Background
Cervical cancer is the fourth most common cancer in
women worldwide after cancer of the breast, colon, and
lung [1]. According to the World Health Organization
(WHO), each year approximately 528,000 new cases are
recorded, and 266,000 deaths occur due to cervical cancer
[2]. Cervical cancer is mainly caused by infection with
high-risk human papillomavirus (HR-HPV) genotypes [3].
With the development of screening and prevention
methods of cervical cancer such as HPV co-testing and
HPV vaccination, early diagnosis programs of cervical
dysplasia and cancer lead to decrease the incidence,
morbidity, and mortality of cervical cancer [4].
However, nearly 50% out of all cervical cancer patients
worldwide are still diagnosed with stages IB2 to IVA
according to International Federation of Gynecology and
Obstetrics (FIGO), whereas about one-third of patients
diagnosed with cervical cancer in Korea presented locally
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advanced stage of the disease [5]. Currently, the standard
treatment guideline for patients with advanced FIGO
stage IIB and more than stage IIB is radiotherapy com-
bined with platinum-based chemotherapy [6]. Unfortu-
nately, these patients have a higher recurrence rate and
a worse survival rate in the first 5 years [5]. Therefore,
it is of great importance to identify a novel biomarker
that can reliably detect cervical cancer and improve
clinical monitoring.
microRNAs (miRs or miRNAs), small non-coding RNAs
consisting of approximately 22 nucleotides, regulate gene
expression by binding to partially or fully complementary
sequences in target mRNAs, resulting in translational in-
hibition or mRNA degradation, respectively [5]. miRNAs
have been suggested to function as oncogenes or tumor
suppressors based on their function of inhibiting the ex-
pression of tumor suppressive or oncogenic target mRNAs,
respectively [6–8]. Numerous studies have shown that dys-
regulation of miRNAs plays an essential role in cell prolifer-
ation, cell cycle regulation, differentiation, and apoptosis
and is related to various tumors such as colon, gastric,
breast, lung, and cervical cancers [9–13].
miR-944 is located in the intron of the tumor protein
p63 gene (TP63) mapped to chromosome 3q28. Previous
reports show that miR-944 functions as an oncogene in
a number human cancers, including cervical cancer,
endometrial cancer, breast cancer, and lung cancer by
promoting cell migration, proliferation, and invasion
[14–17]. However, some studies have reported that
miR-944 can function as a tumor suppressor, inhibiting
migration in colorectal cancer, gastric cancer and breast
cancer [18–20]. In cervical cancer, miR-944 promotes
cell proliferation and migration in CaSki and HeLa cer-
vical cancer cell lines [16, 21]. To our knowledge, there
are no other further studies on the clinical relevance of
miR-944 in cervical cancer, and specifically in terms of
prognostic value.
Human papillomavirus infection is known to one of the
most significant risk factors for cervical cancer [22]. Several
studies suggested that the sustained expression of the two
oncogenic genes E6 and E7 of HPV is involved in cervical
cancer progression by degradation of p53 and deactivation
of retinoblastoma protein (pRB) [23–27]. Recently, miRNA
sequencing data from The Cancer Genome Atlas (TCGA)
was reported that miRNA clusters such as miR-205-5p,
miR-944, miR-200a-5p, miR-30a-5p, miR-338-3p, miR-224-
5p, and miR-193b-3p were associated with cervical cancer
and especially miR-944 was shown the significant difference
between HPV positive and HPV negative cervical cancer
[28]. However, there is no further study of the relationship
between miR-944 and HPV E6/E7 expression in cervical
cancer.
In this study, the prognostic value of miR-944 was in-
vestigated using 116 formalin-fixed paraffin-embedded
(FFPE) cervical cancer tissues and normal tissues. Fur-
thermore, the association between miR-944 and HPV
E6/E7 mRNA-positive or -negative was explored.
Methods
Study population
A total of 66 FFPE cervical cancer tissues and 50 FFPE
normal cervical tissues were collected between January
2010 and December 2014. A total of 66 cervical cancer
cases data on age, tumor size, FIGO stage, lymph node
metastasis, and HPV infection were retrospectively
reviewed from patient electrical medical records. The 50
FFPE normal cervical tissues consisted of 44 patients
with non-cervical, benign, uterine disease and six cervical
cancer patients with tumor-matched non-cancerous tissues
(Table 1). This study was approved by the Institutional
Ethics Committee of Yonsei University Wonju Severance
Christian Hospital (approval no. CR315052), and all sub-
jects provided written informed consent.
Cell culture
Cervical cancer cell lines C33A (HPV-negative), SiHa
(HPV 16), Caski (HPV 16), HeLa (HPV 18), and ME180
(HPV 18, 68) were purchased from the Korean Cell Line
Table 1 Clinical characteristics
Features Cervical cancer, N (%) Normal, N (%)
Total, n (%) 66 (100.0) 50 (100.0)
Age
< 45 years 20 (30.3) 20 (40.0)
≥ 45 years 46 (69.7) 30 (60.0)
Histological type
ADC 7 (10.6)
SCC 59 (89.4)
Tumor size
< 4 cm 30 (45.5)
≥ 4 cm 36 (54.5)
FIGO stage
IA-IIA 29 (43.9)
IIB-IVB 37 (56.1)
Lymph node metastasis
No 35 (53.0)
Yes 31 (47.0)
HPV E6/E7 expression
Negative 12 (18.2)
Positive 54 (81.8)
Survival
Alive 52 (78.8)
Died 14 (21.2)
Abbreviations: FIGO International Federation of Gynecology
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Bank (Seoul, Republic of Korea) and the American Type
Culture Collection (Manassas, VA, USA). Dulbecco’s
modified Eagle’s medium (DMEM) with 10% fetal bovine
serum (FBS; Gibco, Carlsbad, CA, USA) and 1% penicil-
lin/streptomycin (Gibco, Carlsbad, CA, USA) was used
to maintain the cells in tissue culture and the five cell
lines were maintained at 37 °C with 5% CO2.
Deparaffinization of FFPE tissue and total RNA extraction
For total RNA extraction from FFPE cervical tissue,
three to four 10-μm-thick sections were transferred to
1.5 mL tube each. Before extracting RNA, the paraffin
was removed from the tissue sections by adding 160 μL
of deparaffinization solution (Qiagen, Hilden, Germany)
followed by incubation for 3 min at 56 °C. Total RNA
extraction was extracted according to the manufacturer’s
protocol (Qiagen RNeasy FFPE kit, Qiagen). Next, the
concentration of the total RNA was measured with an
Infinite 200 spectrophotometer (Tecan, Salzburg, Austria).
Total RNA was stored at − 80 °C until used.
microRNA RT-qPCR analysis
We used the TaqMan miRNA Reverse Transcription kit
(Applied Biosystems, Foster City, CA, USA) to synthesize
cDNA according to the manufacturer’s instructions. Re-
verse transcription reactions were performed using 10 ng
of total RNA and specific reverse transcription primers
(Life Technologies) for Homo sapiens (hsa)-miR-944
(assay ID 002189), and the internal reference RNU6B
(assay ID 001093). Reverse transcription was performed at
16 °C for 30min, 42 °C for 30min, 85 °C for 5min.
After the reverse transcription, quantitative PCR reac-
tion was performed using the TaqMan microRNA assay
(Applied Biosystems) according to the manufacturer’s
instructions. Briefly, the initiation step of PCR cycling
conditions at 95 °C for 10 min, followed by an amplifica-
tion step of 40 cycles at 95 °C for 15 s and 60 °C for 60 s.
The miR-944 expression levels were calculated via the
comparative cycle threshold (CT) method. The CT values
of miR-944 were normalized to the level of RNU6B.
HPV E6/E7 mRNA RT-qPCR assay
M-MLV reverse transcriptase kit (Invitrogen, Carlsbad,
CA, USA) was used for complementary DNA (cDNA)
synthesis. Briefly, add 0.25 μg random hexamers, 1 μL
10mM dNTP mix, and 5 μL DEPC-treated water and
10 μL total RNA. The mixture was then incubated at 65 °C
for 5min and quickly cooled on ice. After that, 4 μL of 5x
Buffer, 2 μL of 0.1M dithiothreitol (DTT) and 1 μL of
M-MLV Reverse Transcriptase (RT) were added to the first
mix. The reverse transcriptase reaction was carried out at
25 °C for 10 min, at 37 °C for 50 min, and at 70 °C for
15 min.
Detection of HPV E6/E7 mRNA in FFPE cervical tissues
was performed by OPTIMYGENE HPV E6/E7 mRNA
RT-qDx assay kit (Optipharm M&D, Osong, Republic of
Korea), according to the manufacturer’s instructions. The
reverse transcription quantitative PCR (RT-qPCR) assay
was carried out using the CFX96 system (Bio-Rad,
Hercules, CA). Real-time PCR amplification for HPV E6/
E7 mRNA was performed in a total volume of 20 μL, con-
taining 10 μL of 2x Thunderbird probe qPCR mix
(Toyobo, Osaka, Japan), 5 μL primer and TaqMan probe
mixture, 3 μL distilled water and 2 μL template cDNA.
Positive and negative controls were contained per each
procedure. Reaction conditions of real-time PCR were as
follows: 95 °C for 3 min, and 40 cycles of 95 °C for 3 s and
55 °C for 30 s. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as an endogenous control and con-
firmation of mRNA degradation.
The Cancer genome atlas (TCGA) analysis
Raw data for miR-944 and clinical information in cer-
vical cancer were extracted from the TCGA open source
repository website (http://firebrowse.org/) on 01/28/2016.
Variables, such as follow-up times, tumor stage, race, and
reads per million of miR-944 in 180 cervical cancer pa-
tients were included. Information of HPV E6/E7-positive
and HPV E6/E7-negative cervical cancers matched with
patients from TCGA open source repository website was
obtained from the Banister et al. study [29]. The HPV E6/
E7 expression were classified as HPV alpha-9, HPV
alpha-7, and HPV negative cervical cancer based on HPV
E6/E7 expression. The reads per million of miR-944 ac-
cording to HPV E6/E7 expression were analyzed by stu-
dent t-test.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism version 6 software (La Jolla, CA, USA) and
SPSS version 21.0 software (IBM, Armonk, NY, USA).
Wilcoxon matched-pairs singed rank test was performed
for comparison between the paired cervical normal and
cancer tissues. Student’s t-test were conducted for com-
parison between normal and cancer tissues. To identify
whether miR-944 is affected by HPV E6/E7 mRNA posi-
tive or negative cervical cancer tissues, the expression
levels of miR-944 was compared by student’s t-test. To
determine the clinical cut-off value of miR-944 between
cervical cancer and normal tissues, receiver operator char-
acteristic (ROC) curve analysis were performed. Based on
the clinical cut-off value, cases were divided into two
groups according to the expression level of miR-944 (high
miR-944 vs. low miR-944). Potential associations between
the expression of miR-944 and various prognostic parame-
ters were analyzed by the Chi-square test. Survival was
estimated by the Kaplan-Meier method and evaluated by
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the log-rank test. Multivariate analyses of prognostic
values were evaluated using the Cox proportional hazards
model. In all analyses, a P-value of less than 0.05 was con-
sidered statistically significant.
Results
miR-944 expression levels in normal and cancerous
cervical tissues
To explore the expression levels of miR-944 in cervical can-
cer cells, six cervical cancer patients with tumor-matched
non-cancerous tissues were evaluated by RT-qPCR. The
results showed that the expression levels of miR-944 were
significantly higher in cervical cancer tissues than those in
matched non-cancerous cervical tissues (n = 6, P = 0.031;
Fig. 1a). Subsequently, similar expression levels of miR-944
were observed by RT-qPCR in 66 cervical cancer tissues
and 50 normal cervical tissues. The expression levels of
miR-944 in the cervical cancer tissues were significantly
higher than in normal cervical tissues (P < 0.0001; Fig. 1b).
The expression level of miR-944 in cervical cancer and nor-
mal tissues was plotted as a ROC curve to assess cut-off
values for discriminating cervical cancer from normal tis-
sues. At the optimal cut-off point, the area under the curve
(AUC) of miR-944 was 0.79 (P < 0.0001; 95% confidence
interval (CI), 0.71–0.86 (Fig. 1c).
Association between miR-944 expression and HPV
infection status
Since the main cause of cervical cancer is HPV infection,
we investigated whether the expression of miR-944 and
HPV infection status were related. The expression levels
of miR-944 in cervical cancer cell lines with or without
HPV infection were compared. Expression levels of
miR-944 in the HPV-positive cervical cancer cell lines
SiHa (HPV 16-infection), Caski (HPV 16 infection),
HeLa (HPV 18 infection) and ME180 (HPV 18, 68 infec-
tion) were significantly higher than in the HPV-negative
cervical cancer line C33A (P < 0.01, P < 0.01, P < 0.01,
and P < 0.001, respectively), supporting the hypothesis
that HPV infection may affect miR-944 expression levels
(Additional file 1).
Next, the expression levels of miR-944 in the 66 FFPE
cervical cancer tissues according to HPV infection
status were investigated. Among 54 HPV E6/E7
mRNA expression-positive and 12 HPV E6/E7 mRNA
expression-negative cancer tissues, the expression
levels of miR-944 were significantly up-regulated in
HPV E6/E7 mRNA expression-positive cancer tissues
(P = 0.02; Fig. 2). Furthermore, 171 cervical cancer tissues
comprised of samples from various races and HPV types
(TCGA data) classified by HPV-E6/E7 based genes were
additionally analyzed (Additional file 2). Similarly, the
expression levels of miR-944 in TCGA data were also
significantly up-regulated in HPV-E6/E7 positive cancer
tissues, especially alpha 9 and alpha 7 species (P < 0.0001;
Additional file 3).
Associations between miR-944 expression and
clinicopathological characteristics
To investigate the association between the miR-944 ex-
pression levels and clinicopathological characteristics,
Chi-square test was used to analyze data from 66 cer-
vical cancer patients. miR-944 expression levels showed
no association with age and histological type (P = 0.815
and P = 0.174). However, miR-944 expression levels
showed significant association with tumor size, FIGO
stage, and lymph node metastasis, indicating their use-
fulness as prognostic parameters (P = 0.026, P = 0.042,
and P = 0.030; Table 2). The expression of miR-944 was
low in tumors less than 4 cm (76.7%), in the early FIGO
(A) (B) (C)
Fig. 1 Relative miR-944 expression in FFPE cervical cancer tissues and normal cervical tissues. a Relative miR-944 expression in paired samples (n
= 6). The mean miR-944 expression level in the cervical cancer tissues was significantly higher than the pair-matched non-cancerous cervical
tissues (P = 0.031). b The relative miR-944 expression levels were compared between cervical cancer (n = 66) and normal cervical tissues (n = 50).
The miR-944 expression levels in cervical cancer tissues were significantly higher than those in normal cervical tissues (P < 0.0001). c Receiver
operator characteristic curve analysis for determining cut-off value is distinguishing normal and cancer cells was performed. Optimal cut-off point
for miR-944 with an AUC of 0.79 (P < 0.0001; 95% confidence interval [CI], 0.71–0.86). * P < 0.05, ** P < 0.01, and *** P < 0.001
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stage (75.9%), and in the absence of lymph node metasta-
sis (74.3%). Interestingly, patients with tumors larger than
4 cm, advanced FIGO stage, and lymph node metastasis
showed low and high of miR-944 levels at similar percent-
ages (50 and 50% for larger than 4 cm tumors, 51.4 and
48.6% for advanced FIGO stage, and 48.4 and 51.6% for
lymph node metastasis). Not only the conventional prog-
nostic parameters but also biological characteristics of
miR-944 provide another additional information. There-
fore, we further analyzed whether miR-944 is useful as a
prognostic marker that can provide additional information
to existing prognostic factors.
Association between miR-944 expression and patient
survival
To explore overall survival in patients with high and low
expression of miR-944, overall survival time was obtained
from the date of the initial surgery to time of death.
Kaplan-Meier survival analysis showed poor prognosis
with high miR-944 expression (Log-rank test, P = 0.003).
A 5-year survival rate of 90.2% in patients with low
miR-944 expression levels (n = 41) ranged from 49.9 to
59.6months (mean, 54.8months), whereas 5-year survival
rate of 60.0% in patients with high miR-944 expression
levels (n = 25) ranged from 29.8 to 49.8months (mean,
39.8months) (Fig. 3a).
To compare the prognostic parameters and miR-944,
which is a newly found prognostic marker, Cox propor-
tional hazards regression was used to investigating the
association between survival time of patients and clinical
parameters together with miR-944 expression. Using
univariate analysis, high miR-944 expression levels and
three clinicopathological parameters which were tumor
size (HR = 5.6, 95% CI 1.3–25.2, P = 0.024), FIGO stage
(HR = 11.8, 95% CI 1.5–90.2, P = 0.018), and lymph node
metastasis (HR = 8.2, 95% CI 1.8–36.5, P = 0.006) were
associated with poor prognosis of cervical cancer. All
significant parameters were further analyzed using
multivariate analysis. The results revealed that FIGO
stage (HR = 9.1, 95% CI 1.2–71.1, P = 0.034) and high
miR-944 expression (HR = 3.5, 95% CI 1.1–11.2, P =
0.034) could be independent prognostic factors for the
patients with cervical cancer (Table 3).
In an advanced FIGO stage (n = 37), Kaplan-Meier
survival analysis revealed the poor prognosis of patients
with high miR-944 expression levels (Log-rank test, P =
0.01). The 5-year survival rate in patients with low
miR-944 expression levels (n = 19) was 84.2% and
ranged from 42.7 to 60.3 months (mean, 51.5 months),
whereas the 5-year survival rate in patients with high
miR-944 expression levels (n = 18) was 44.4% and
ranged from 19.9 to 44.1 months (mean, 32.0 months)
(Fig. 3b).
Fig. 2 Relative expression of miR-944 in HPV E6/E7 mRNA positive
and negative cervical cancer tissues. Comparison of the relative
expression level of miR-944 among the HPV E6/E7 mRNA positive
cervical cancer tissues (n = 67), HPV E6/E7 mRNA negative cervical
cancer tissues (n = 12), and normal tissues (n = 50). The expression
level of miR-944 in HPV E6/E7 mRNA positive cervical cancer tissues
was significantly higher than in HPV E6/E7 mRNA negative cervical
cancer tissues (P = 0.02). * P < 0.05, ** P < 0.01, and *** P < 0.001
Table 2 Association between the miR-944 expression levels and
clinicopathological characteristics of patients with cervical cancer
Features No. (%) miR-944 expression P
(n = 66) Low, n (%) High, n (%)
No. of patients 66 41 (62.1) 25 (37.9)
Age 0.815
< 45 years 20 12 (60.0) 8 (40.0)
≥ 45 years 46 29 (63.0) 17 (37.0)
Histological type 0.174
ADC 7 6 (85.7) 1 (12.9)
SCC 59 35 (59.3) 24 (40.7)
Tumor size 0.026
< 4 cm 30 23 (76.7) 7 (23.3)
≥ 4 cm 36 18 (50.0) 18 (50.0)
FIGO stage 0.042
IA-IIA 29 22 (75.9) 7 (24.1)
IIB-IVB 37 19 (51.4) 18 (48.6)
Lymph node metastasis 0.030
No 35 26 (74.3) 9 (25.7)
Yes 31 15 (48.4) 16 (51.6)
Abbreviation; FIGO International Federation of Gynecology; P, Chi-square p-value
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Discussion
In this study, we investigated miR-944 expression levels
in FFPE cervical cancer and normal tissues by RT-qPCR
methods, and the result showed poor prognosis in
patients with high miR-944 expression levels and in an
advanced stage of cervical cancer. In addition, we dem-
onstrated that there was an association between high ex-
pression levels of miR-944 and expression levels of HPV
oncogene E6/E7 in HPV-positive cervical cancer cells by
analysis of FFPE cervical cancer tissues and TCGA data.
The expression levels of miR-944 were significantly
higher in cervical cancer tissues as compared to those in
paired non-cancerous tissues (n = 6) (Fig. 1), which
suggested that miR-944 plays a role in tumorigenesis
through clinical cervical cancer tissues. Xie et al. (2015)
also had shown that high miR-944 expression levels are
associated with tumorigenesis of cervical cancer, based
on analysis of cervical cancer cell lines (Caski and HeLa)
[16]. We further examined 66 cervical cancer and 50
normal FFPE samples and showed that the expression of
miR-944 in cervical cancer was up-regulated which was
in line with previous reports [16].
To gain insight into the clinical significance and prog-
nostic value of miR-944, we investigated the relationship
between miR-944 expression levels and the clinicopatho-
logical characteristics of cervical cancer patients and
found that expression of miR-944 was firmly related to
the tumor size, FIGO stage, and lymph node metastasis
(Table 2). Ma et al. reported that up-regulation of
miR-944 has also been associated with lymph node
metastasis and advanced stage of lung squamous cell
carcinoma [30].
Furthermore, survival analysis of cervical cancer
patients showed that high expression levels of miR-944
were associated with poor survival prognosis (Fig. 3a).
As a prognostic marker, FIGO stage and high miR-944
expression levels were shown useful prognostic indica-
tors of poor survival (Table 3). Notably, in advanced
cervical cancer, high miR-944 expression levels were sig-
nificantly poorer prognosis than low miR-944 expression
levels (Fig. 3b).
Previous studies have attempted to identify the mRNA
target of miR-944 in cervical cancer, and Xie et al.
showed that miR-944 has two target genes, HECT do-
main ligase W2 (HECW2), which are known to regulate
p63 stabilization, and S100P binding protein (S100PBP),
which is known to reduce adhesion and invasion.
miR-944 was predicted to play an oncogenic role in
Fig. 3 Kaplan-Meier survival curve for patients with cervical cancer according to miR-944 expression. a High or low miR-944 expression level were
determined using the cut-off value of miR-944 in cervical cancer and normal tissues. High miR-944 expression level group showed poor survival
rates compared to low miR-944 expression level group (log-rank test, P = 0.003). b Among the 37 patients with an advanced FIGO stage,
including of 19 patients with low miR-944 expression and 18 with high miR-944 expression, the overall survival rate was 84.2 and 44.4% (log-rank
test, P = 0.01)
Table 3 Univariate and multivariate analysis of prognostic
factors together with miR-944 expression in cervical cancer
Features Overall survival
Univariate analysis Multivariate analysis
HR 95% CI P HR 95% CI P
Ages
< 45 years vs. ≥ 45 years 2.8 0.6–12.4 0.18
Histological type
ADC vs. SCC 1.5 0.2–11.8 0.68
Tumor size
< 4 cm vs. ≥ 4 cm 5.6 1.3–25.2 0.024
FIGO stage
<IIb vs. ≥ IIb 11.8 1.5–90.2 0.018 9.1 1.2–71.1 0.034
Lymph node metastasis
no vs. yes 8.2 1.8–36.5 0.006
miR-944 expression
Negative vs. Positive 4.7 1.5–15.0 0.009 3.5 1.1–11.2 0.034
Abbreviations: ADC Adenocarcinoma, SCC Squamous cell carcinoma, FIGO
International Federation of Gynecology
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cervical cancer malignancy by repressing these two
genes (HECW2 and S100PBP) that function as a tumor
suppressors [16].
Several studies have reported that the expression levels
of some miRNAs are associated with poor prognosis in
cervical cancer, such as downregulation of miR-335 from
Wang et al. [31], down-regulation of miR-145 and up-
regulation of miR-9 from Azizmohammadi et al. [32].
Recently, Jiang et al. suggested that down-regulation of
circulating miR-101 is associated with poor prognosis of
cervical cancer [33]. Our study also suggests that high
expression of miR-944 could be of clinical relevance for
poor prognosis. The miR-944 expression has been analyzed
in colorectal, bladder, and breast cancer. High miR-944 ex-
pression levels have been associated with tumor recurrence
in colorectal cancer [34] and chemo-resistance in bladder
cancer [35]. He et al. found that miR-944 is significantly
up-regulated in the blood and tumor tissues of breast can-
cer patients [36]. Like our study, miR-944 is remarkable
tumor-associated microRNA.
Interestingly, in our study, miR-944 expression in HPV
E6/E7 mRNA-positive cervical cancer was higher than
that in HPV E6/E7 mRNA-negative cervical cancer (P =
0.02; Fig. 2). Meanwhile, among five cervical cancer cell
lines, the expression of miR-944 in cervical cancer cell
lines with HPV infection (SiHa and HeLa, Caski, and
ME180) was significantly higher than that in the cervical
cancer cell line without HPV infection (C33A) (Additional
file 1) as well as TCGA data (Additional file 3), analyzed
by using individual miR-944 reads and HPV E6/E7 expres-
sion status. It suggests that up-regulation of miR-944 is
associated with HPV infection and the carcinogenic pro-
cesses of the E6 and E7 genes. Recently, microRNA heat
map categorized by HPV infection and cervical cancer
subtypes from TCGA projects also showed that the levels
of miR-944, miR-767-5p, and miR-105-5p between
HPV-positive and negative cancer were distinctively
expressed [28]. Taken together, our results supported that
miR-944 expression levels are closely related to HPV
infection.
HPV E6 protein was found to bind p53 and inhibit cell
apoptosis. HPV E7 proteins binding to retinoblastoma
protein (pRb) interferes with cell cycle regulation [36, 37].
We found that miR-944 expression was associated with
HPV E6/E7 mRNA. However, the relationship between
miR-944 and p53 or pRb, which showed a relationship
with HPV E6/E7, in cervical cancer progression was not
evaluated. Further studies are needed to evaluate the func-
tional role of miR-944 with p53 or pRb to understand the
progression of cervical cancer.
The limitation of this study was the small sample size
with single institution. Nevertheless, this study was valu-
able that miR-944 was shown potential marker comple-
menting conventional clinical prognostic parameters and
the relation to HPV E6/E7 positive cervical cancer tis-
sues. It may be worthwhile to conduct replication to
clarify our findings with sufficient clinical sample set.
Conclusions
In conclusion, our results show that miR-944 was highly
expressed in cervical cancer tissues and this was associ-
ated with FIGO stage, lymph node metastasis, and tumor
size. Moreover, elevated expression of miR-944 was corre-
lated with poor survival. Therefore, our data suggest that
miR-944 could be used as a prognostic marker in cervical
cancer.
Additional files
Additional file 1: Relative expression of miR-944 in HPV-infected and
HPV non-infected cervical cancer cell lines. The relative expression level
of miR-944 was evaluated in five types of cervical cancer cell lines: C33A,
SiHa, Caski, HeLa, and ME180. miR-944 was significantly up-regulated in
SiHa (HPV 16), Caski (HPV 16), HeLa (HPV 18), and ME-180 (HPV 18, 68)
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